Cover Image
Market Research Report
Product code 
1018444

Scars - Pipeline Insight, 2021

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Scars - Pipeline Insight, 2021
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's, "Scars - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Scars Understanding

Scars: Overview

Scars form as part of the healing process after your skin has been cut or damaged. The skin repairs itself by growing new tissue to pull together the wound and fill in any gaps caused by the injury. Scar tissue is made primarily of a protein called collagen. Scars develop in all shapes and sizes. Some scars are large and painful, while some are barely visible. When a scar first develops on lighter skin, it's usually pink or red. Over time, the pinkish color fades, and the scar becomes slightly darker or lighter than the color of the skin. In people with dark skin, scars often appear as dark spots. Sometimes scars itch, and they may be painful or tender.

"Scars - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scars pipeline landscape is provided which includes the disease overview and Scars treatment guidelines. The assessment part of the report embraces, in depth Scars commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scars collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Scars R&D. The therapies under development are focused on novel approaches to treat/improve Scars.

Scars Emerging Drugs Chapters

This segment of the Scars report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Scars Emerging Drugs

  • STP 705: Sirnaomics

STP 705 is a siRNA therapeutic comprising of two oligonucleotides, being developed by Sirnaomics and General Research Laboratory (GRL). The drug is currently in phase 2 of development stage for the treatment of Hypertrophic scars.

  • Botulinum toxin E: Bonti

A next generation botulinum neurotoxin serotype E (BoNT/E), is being developed by Bonti for the treatment of glabellar frown lines, musculoskeletal pain and Scars.

Further product details are provided in the report……..

Scars: Therapeutic Assessment

This segment of the report provides insights about the different Scars drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Scars

There are approx. 10+ key companies which are developing the therapies for Scars. The companies which have their Scars drug candidates in the most advanced stage, i.e. phase II include, Sirnaomics.

  • Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Scars pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scars: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Scars therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scars drugs.

Scars Report Insights

  • Scars Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Scars Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Scars drugs?
  • How many Scars drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scars?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Scars therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Scars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Sirnaomics
  • Roche
  • OliX Pharmaceuticals
  • Bonti
  • FirstString Research
  • Cellastra
  • Scarless Laboratories
  • Hugel
  • RXi Pharmaceuticals, Corp.
  • Olix Pharmaceuticals, Inc.
  • Lemonex
  • Krystal Biotech, Inc.
  • AiViva BioPharma, Inc.
  • AdiSave Inc.

Key Products

  • STP 705
  • RG 6354
  • OLX 101A
  • Botulinum toxin E
  • ACT 1
  • Research programme: anti-scarring gene therapy
  • SLI F06
  • BMT101
  • RXI-109
  • OLX10010
  • LEM-S401
  • KB301
  • AIV001
Product Code: DIPI1040

Table of Contents

Introduction

Executive Summary

Scars: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Scars - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

  • Scars companies' collaborations, Licensing, Acquisition -Deal Value Trends

Scars Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

  • Comparative Analysis

STP 705: Sirnaomics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

OLX 101A: OliX Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

LEM S401: Lemonex

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Scars Key Companies

Scars Key Products

Scars- Unmet Needs

Scars- Market Drivers and Barriers

Scars- Future Perspectives and Conclusion

Scars Analyst Views

Scars Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Scars
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Scars
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products